Background: Actinic keratosis (AK) is a sun-induced skin lesion that may progress to invasive squamous cell carcinoma of the skin. Recently, the Actinic Keratosis Quality of Life questionnaire (AKQoL) was designed for patients with AK in Denmark as a specific quality of life instrument for AK patients. Objective: The objective of this study was to adapt the AKQoL for the German language region of Switzerland and to evaluate its psychometric properties (validity, reliability). Methods: Translation and cultural adaptation of the questionnaire were assessed by using the technique of cognitive interviewing. During the translation process, 34 patients with AK from the Department of Dermatology, University Hospital Zurich, were interviewed in 3 sessions of cognitive interviewing. The translated questionnaire was then distributed together with the Dermatology Life Quality Index (DLQI) to a second group of 113 patients for validation and reliability testing. Within this group, we measured the internal consistency by the Cronbach coefficient α and Spearman correlation coefficient between the AKQoL and the DLQI. Results: The problems encountered during the translation process led to changes in 5 categories as described by Epstein: stylistic changes, change in breadth, change in actual meaning, change in frequency and time frame, change in intensity. We found a Cronbach α of 0.82, an acceptable internal consistency. The Spearman correlation coefficient between total scores of AKQoL and DLQI was 0.57. Conclusion: We culturally adapted and validated a Swiss (German) version of the AKQoL questionnaire applicable for the population of a university center in Switzerland to measure and monitor the quality of life in patients with AK.

Keywords:
Actinic Keratosis Quality of Life questionnaire, Cognitive interviewing, Actinic keratosis, Health-related quality of life, Skin cancer
1.
Marks R, Rennie G, Selwood TS: Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988; 1: 795–797.
2.
Ackerman AB, Mones JM: Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006; 155: 9–22.
3.
Röwert-Huber J, Patel MJ, Forschner T, et al: Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007; 156(suppl 3): 8–12.
4.
Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A: The natural history of actinic keratosis: a systematic review. Br J Dermatol 2013; 169: 502–518.
5.
Frost CA, Green AC: Epidemiology of solar keratoses. Br J Dermatol 1994; 131: 455–464.
6.
Schaefer I, Augustin M, Spehr C, Reusch M, Kornek T: Prevalence and risk factors of actinic keratoses in Germany – analysis of multisource data. J Eur Acad Dermatol Venereol 2014; 28: 309–313.
7.
Marks R, Ponsford MW, Selwood TS, Goodman G, Mason G: Non-melanotic skin cancer and solar keratoses in Victoria. Med J Aust 1983; 2: 619–622.
8.
Harvey I, Frankel S, Marks R, Shalom D, Nolan-Farrell M: Non-melanoma skin cancer and solar keratosis. II. Analytical results of the South Wales Skin Cancer Study. Br J Cancer 1996; 74: 1308–1312.
9.
Stockfleth E: The importance of treating the field in actinic keratosis. J Eur Acad Dermatol Venereol 2017; 31(suppl 2): 8–11.
10.
Hofbauer G, Anliker M, Boehncke WH, et al: Swiss clinical practice guidelines on field cancerization of the skin. Swiss Med Wkly 2014; 144:w14026.
11.
Werner RN, Stockfleth E, Connolly SM, et al: Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis – International League of Dermatological Societies in cooperation with the European Dermatology Forum – short version. J Eur Acad Dermatol Venereol 2015; 29: 2069–2079.
12.
Fleming P, Zhou S, Bobotsis R, Lynde C: Comparison of the treatment guidelines for actinic keratosis: a critical appraisal and review. J Cutan Med Surg 2017; 21: 408–417.
13.
Esmann S, Vinding GR, Christensen KB, Jemec GB: Assessing the influence of actinic keratosis on patients’ quality of life: the AKQoL questionnaire. Br J Dermatol 2013; 168: 277–283.
14.
Weinstock MA, Lee KC, Chren MM, Marcolivio K; VATTC Trial Group: Quality of life in the actinic neoplasia syndrome: The VA Topical Tretinoin Chemoprevention (VATTC) Trial. J Am Acad Dermatol 2009; 61: 207–215.
15.
Cerio R: The importance of patient-centred care to overcome barriers in the management of actinic keratosis. J Eur Acad Dermatol Venereol 2017; 31(suppl 2): 17–20.
16.
Goldenberg G: Treatment considerations in actinic keratosis. J Eur Acad Dermatol Venereol 2017; 31(suppl 2): 12–16.
17.
Guyatt GH, Feeny DH, Patrick DL: Measuring health-related quality of life. Ann Intern Med 1993; 118: 622–629.
18.
Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–216.
19.
Hadley J, Tristani-Firouzi P, Hull C, Florell S, Cotter M, Hadley M: Results of an investigator-initiated single-blind split-face comparison of photodynamic therapy and 5% imiquimod cream for the treatment of actinic keratoses. Dermatol Surg 2012; 38: 722–727.
20.
Gholam P, Kroehl V, Enk AH: Dermatology Life Quality Index and side effects after topical photodynamic therapy of actinic keratosis. Dermatology 2013; 226: 253–259.
21.
Hanke WC, Norlin JM, Mark Knudsen K, Larsson T, Stone S: Quality of life in treatment of AK: treatment burden of ingenol mebutate gel is small and short lasting. J Dermatolog Treat 2016; 27: 450–455.
22.
Grandi V, Baldi I, Cappugi P, Mori M, Pim-pinelli N: Indole 3-acetic acid-photodynamic therapy in the treatment of multiple actinic keratoses: a proof of concept pilot study. Photodiagnosis Photodyn Ther 2016; 16: 17–22.
23.
Esmann S, Jemec GB: Management of actinic keratosis patients: a qualitative study. J Dermatolog Treat 2007; 18: 53–58.
24.
Willis GB: Cognitive Interviewing, a “How to” Guide. Research Triangle Park, Research Triangle Institute, 1999, pp 2–11.
25.
Beaton DE, Bombardier C, Guillemin F, Ferraz MB: Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976) 2000; 25: 3186–3191.
26.
Perneger TV, Courvoisier DS, Hudelson PM, Gayet-Ageron A: Sample size for pre-tests of questionnaires. Qual Life Res 2015; 24: 147–151.
27.
Patrick DL, Burke LB, Gwaltney CJ, et al: Content validity – establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report. 2. Assessing respondent understanding. Value Health 2011; 14: 978–988.
28.
Epstein J, Osborne RH, Elsworth GR, Beaton DE, Guillemin F: Cross-cultural adaptation of the Health Education Impact Questionnaire: experimental study showed expert committee, not back-translation, added value. J Clin Epidemiol 2015; 68: 360–369.
29.
Wild D, Grove A, Martin M, et al: Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 2005; 8: 94–104.
30.
Acquadro C, Conway K, Hareendran A, Aaronson N; European Regulatory Issues and Quality of Life Assessment Group: Literature review of methods to translate health-related quality of life questionnaires for use in multinational clinical trials. Value Health 2008; 11: 509–521.
31.
Danielsen AK, Pommergaard HC, Burcharth J, Angenete E, Rosenberg J: Translation of questionnaires measuring health related quality of life is not standardized: a literature based research study. PLoS One 2015; 10: e0127050.
32.
Presser S, Rothgeb JM, Couper MP, Lessler JT, Martin E, Singer E: Methods for Testing and Evaluating Survey Questionnaires. Hoboken, Wiley & Sons, 2004, pp 453–473.
33.
Bland JM, Altman DG: Cronbach’s alpha. BMJ 1997; 314: 572.
34.
Cortina JM: What is coefficient alpha? An examination of theory and applications. J Appl Psychol 1993; 78: 98–104.
35.
Erlendsson AM, Egekvist H, Lorentzen HF, et al: Actinic keratosis: a cross-sectional study of disease characteristics and treatment patterns in Danish dermatology clinics. Int J Dermatol 2016; 55: 309–316.
36.
Tennvall GR, Norlin JM, Malmberg I, Erlendsson AM, Hædersdal M: Health related quality of life in patients with actinic kerato sis – an observational study of patients treated in dermatology specialist care in Denmark. Health Qual Life Outcomes 2015; 13: 111.
37.
Alarcon I, Vinding GR, Christensen KB, et al: Spanish version of the Actinic Keratosis Quality of Life questionnaire. J Eur Acad Dermatol Venereol 2017; 31: 986–991.
38.
Longo Imedio I, Serra-Guillen C: Adaptation and validation of the Spanish version of the Actinic Keratosis Quality of Life questionnaire. Actas Dermosifiliogr 2016; 107: 474–481.
39.
Miller IM, Vinding G, Zarchi K, Esmann S, Murrell DF, Jemec GB: Differences in disease-specific quality of life in patients with actinic keratosis in Australia and Denmark. Acta Dermatovenerol Croat 2016; 24: 25–28.
40.
Holm EA, Esmann S, Jemec GB: Does visible atopic dermatitis affect quality of life more in women than in men? Gend Med 2004; 1: 125–130.
41.
Cima K, Twiss J, Speich R, et al: The German adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). Health Qual Life Outcomes 2012; 10: 110.
42.
Hirschmüller A, Steffen K, Fassbender K, et al: German translation and content validation of the OSTRC Questionnaire on overuse in-juries and health problems. Br J Sports Med 2017; 51: 260–263.
43.
Sgroi M, Däxle M, Kocak S, Reichel H, Kappe T: Translation, validation, and cross-cultural adaption of the Western Ontario Meniscal Evaluation Tool (WOMET) into German. Knee Surg Sports Traumatol Arthrosc 2017, Epub ahead of print.
44.
Piault E, Doshi S, Brandt BA, et al: Linguistic validation of translation of the Self-Assessment Goal Achievement (SAGA) questionnaire from English. Health Qual Life Outcomes 2012; 10: 40.
45.
Blackford S, Roberts D, Salek MS, Finlay A: Basal cell carcinomas cause little handicap. Qual Life Res 1996; 5: 191–194.
46.
Rhee JS, Matthews BA, Neuburg M, Smith TL, Burzynski M, Nattinger AB: Skin cancer and quality of life: assessment with the Dermatology Life Quality Index. Dermatol Surg 2004; 30: 525–529.
47.
Lewis V, Finlay AY: 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004; 9: 169–180.
48.
Rhee JS, Matthews BA, Neuburg M, Logan BR, Burzynski M, Nattinger AB: The skin cancer index: clinical responsiveness and predictors of quality of life. Laryngoscope 2007; 117: 399–405.
49.
Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY: The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159: 997–1035.
50.
Steinbauer J, Koller M, Kohl E, Karrer S, Landthaler M, Szeimies RM: Quality of life in health care of non-melanoma skin cancer – results of a pilot study. J Dtsch Dermatol Ges 2011; 9: 129–135.
51.
Nijsten T: Dermatology life quality index: time to move forward. J Invest Dermatol 2012; 132: 11–13.
52.
Takahashi N, Suzukamo Y, Nakamura M, et al: Japanese version of the Dermatology Life Quality Index: validity and reliability in patients with acne. Health Qual Life Outcomes 2006; 4: 46.
53.
Jobanputra R, Bachmann M: The effect of skin diseases on quality of life in patients from different social and ethnic groups in Cape Town, South Africa. Int J Dermatol 2000; 39: 826–831.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.